Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

ChemR23 and interrupt the early steps associated with the development of psoriatic dermal inflammation and other inflammatory diseases.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN (now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in a Phase I clinical trial. ChemoCentryx also has several programs in advanced preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Certain statements in this pres
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Calif. , Aug. 20, 2014 ... will be using advanced, ventilator technology from Covidien ... to care for patients. The ... more naturally, compared to conventional mechanical ventilation, and ... soon as possible. Patients on mechanical ventilation are ...
(Date:8/20/2014)... Aug. 20, 2014 Children aren,t the ... vaccinations to help prevent disease. The Centers for ... all adults, but currently, many adults are not ... National Immunization Awareness Month, and the American Lung ... especially those with lung disease, to talk with ...
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
Breaking Medicine Technology:Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Market Report of Pralmorelin 2
(Date:8/20/2014)... of chronic users of codeine-containing cough syrups (CCS) ... white matter and associates these changes with increased ... diffusuion tensor imaging (DTI) (an MR imaging technique), ... matter integrity of chronic CCS users. Deficits were ... the inferior fronto-occipital fasciculus, which other studies have ...
(Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... exercise may help older women avoid a condition that causes ... active postmenopausal women had a 10 percent lower risk of ... researchers report in the Aug. 20 issue of the ... enjoyed this protection against the heart rhythm disorder even if ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The Board ... Perkins Eastman is pleased to announce the ... services in China and the surrounding region. ... Richard Sprow AIA has relocated to the ... career in healthcare planning and design and to better ...
(Date:8/20/2014)... PITTSBURGH, Aug. 20, 2014 A common approach to ... blood did not improve survival chances for people who ... experts at the University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2
... backboned animals, but recent study has shown that things ... of their skeletal development. These findings will be published ... scientists were able to find the very same protein, ... which is also found in all vertebrates with backbones ...
... that babies breastfed for six months have reduced respiratory ... was conducted by investigators at UC Davis Children's Hospital, ... Pediatrics, Center for Child Health Research. ,In ... Davis Children's Hospital, lead author, "We found that babies ...
... by the Canadian snacks company Frito Lay Canada has launched ... South Asians. ,40 chip flavours created and tested ... and wasabi for test marketing. Stores were stocking these chops ... South Asians annually spends $12.6 billion on retail goods and ...
... technique to test and identify 'dead regions' in the ... children is being developed by Karolina Kluk, a Cambridge ... for development of individualized hearing aids for children. ... patients regarding their sensitivity to a range of tones ...
... skin cancer is the most common tumor to be diagnosed. It ... University Hospital of Navarra. // Sadly, the incidence melanoma has been ... killer of women aged between 19 and 50 years. In the ... 9000 in just 10 years. ,Two main factors regarded ...
... use birth control patch are twice as likely to develop clots ... found. Recently, another study conducted on similar grounds // has revealed ... sides, women who use the patch have been urged to discus ... ,Women who use the patch may be at an increased ...
Cached Medicine News:Health News:New Test Offers Hope in Effective Hearing Aid Design for Babies 2Health News:New Technique Could Revolutionize Melanoma Diagnosis and Treatment 2
... Cascade M-4 is a manual ... all routine clotting assays - PTs, ... Designed for easy, inexpensive, low-volume testing, ... but big on features, offering time ...
... STA is a fully-automated, coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
... ACL Advance can reduce costs ... lab. With its superior ACL ... easy to use coagulation analyzer ... Plus, the protective transparent cover ...
... Pro Professional Hemoglobin Testing System consists of ... strips, used in measuring total hemoglobin, from ... Pro provides the precision, accuracy and cost ... Pro Professional Hemoglobin Testing System is portable ...
Medicine Products: